Showing 231 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Autoimmune Disorders

Systemic Lupus Erythematosus, Lupus Nephritis Phase 1, Phase 2 Spain

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Chronic Spontaneous Urticaria Phase 3 Spain
France
United States
Germany
Korea, Republic of
View All

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Polymyalgia Rheumatica Phase 3 Australia
United States
Switzerland

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

Pulmonary Arterial Hypertension Phase 2 Germany
Poland

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

Hypercholesterolemia Phase 3 United States

A Randomized Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis

Psoriasis Not Applicable Korea, Republic of

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Hepatic Impairment Phase 1 Hungary

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Primary Prevention of Atherosclerotic Cardiovascular Disease Phase 3 United States
Canada
Hong Kong
Australia
View All

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

Breast Cancer France

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies

Heterozygous or Homozygous Familial Hypercholesterolemia Phase 3 Netherlands
United States
Switzerland
Russian Federation
Slovenia
Norway
Spain
Hungary
View All